Rheumatoid Arthritis
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
The aim of this study was to identify several specific reliable metabolites for predicting the response of RA patients to TNF-α inhibitors (TNFi) and abatacept (ABT), using capillary electrophoresis-time-of-flight mass spectrometry (CE-TOFMS).
|
31143951 |
2019 |
Rheumatoid Arthritis
|
0.700 |
Biomarker
|
disease |
BEFREE |
The TNF-transgenic (TNF-Tg) murine model of RA develops both inflammatory arthritis and an ILD that mimics a cellular nonspecific interstitial pneumonia pattern dominated by an interstitial accumulation of inflammatory cells with minimal-to-absent fibrosis.
|
31659014 |
2019 |
Rheumatoid Arthritis
|
0.700 |
Biomarker
|
disease |
BEFREE |
In this study, we investigated the association between rheumatoid factor (RF) and anti-citrullinated protein autoantibody (ACPA) status and the discontinuation of tumor necrosis factor inhibitors (TNFi) therapy due to insufficient response in bio-naïve rheumatoid arthritis (RA) patients.
|
31179526 |
2019 |
Rheumatoid Arthritis
|
0.700 |
Biomarker
|
disease |
BEFREE |
Tumor necrosis factor alpha (TNFα) and its type 1 receptor (TNFR1) are implicated in several autoimmune diseases, including rheumatoid arthritis, and are associated with complications at the cardiovascular level.
|
30897335 |
2019 |
Rheumatoid Arthritis
|
0.700 |
Biomarker
|
disease |
BEFREE |
These findings showed that exercise and anti-TNF had differential effects on CVD risk in RA, and should be combined for optimal CVD risk reduction.
|
30421104 |
2019 |
Rheumatoid Arthritis
|
0.700 |
Biomarker
|
disease |
BEFREE |
Restored and Enhanced Memory T Cell Immunity in Rheumatoid Arthritis After TNFα Blocker Treatment.
|
31105703 |
2019 |
Rheumatoid Arthritis
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Patients with rheumatoid arthritis (RA) can be successfully treated with tumor necrosis factor (TNF) inhibitors, including the monoclonal antibody adalimumab.
|
30700574 |
2019 |
Rheumatoid Arthritis
|
0.700 |
Biomarker
|
disease |
BEFREE |
We used a TNF-α reliant mouse model of RA.
|
30778120 |
2019 |
Rheumatoid Arthritis
|
0.700 |
Biomarker
|
disease |
BEFREE |
Accumulating evidence shows the safety of Tumor Necrosis Factor inhibitors in pregnant RA patients and patients with a wish to conceive.
|
31779849 |
2019 |
Rheumatoid Arthritis
|
0.700 |
Biomarker
|
disease |
BEFREE |
The objective of this study was to identify new genetic variation associated with the clinical response to anti-TNF therapy in RA.
|
31312201 |
2019 |
Rheumatoid Arthritis
|
0.700 |
Biomarker
|
disease |
BEFREE |
To examine the influence of smoking on biologics treatment against different therapeutic targets, such as TNFα, IL-6, and T cell, in rheumatoid arthritis (RA) and elucidate the underlying molecular mechanism.
|
30591403 |
2019 |
Rheumatoid Arthritis
|
0.700 |
Biomarker
|
disease |
BEFREE |
Evidence supports the clinical benefits of early aggressive biologic treatment in patients with rheumatoid arthritis (RA) who have an inadequate response to conventional synthetic disease-modifying antirheumatic drugs (csDMARDs), but the cost-effectiveness of early intervention with originator biologics such as tumor necrosis factor inhibitors (TNFis) or their biosimilars has not been well studied.
|
31148057 |
2019 |
Rheumatoid Arthritis
|
0.700 |
Biomarker
|
disease |
BEFREE |
Hypothesizing that FLSs stimulated with 2GF + TNF would accumulate <i>in vivo</i> in RA, we determined the therapeutic effects of TNF and CDK4/6 inhibitors.
|
30828336 |
2019 |
Rheumatoid Arthritis
|
0.700 |
Biomarker
|
disease |
BEFREE |
The effect of non-TNF-targeted biologics on vascular dysfunction in rheumatoid arthritis: A systematic literature review.
|
30844558 |
2019 |
Rheumatoid Arthritis
|
0.700 |
Biomarker
|
disease |
BEFREE |
Pharmacodynamic biomarkers and differential effects of TNF- and GM-CSF-targeting biologics in rheumatoid arthritis.
|
30358109 |
2019 |
Rheumatoid Arthritis
|
0.700 |
Biomarker
|
disease |
BEFREE |
To assess the hypothesis if tocilizumab (TCZ) is effective on disease activity, and also its effect in fatigue and other clinical and psychological disease-related factors in patients with rheumatoid arthritis (RA) treated with TCZ.A 24-week, multicenter, prospective, observational study in patients with moderate to severe RA receiving TCZ after failure or intolerance to disease-modifying antirheumatic drugs or tumor necrosis factor-alpha was conducted.Of the 122 patients included, 85 were evaluable for effectiveness (85% female, 51.9 ± 12.5 years, disease duration 8.7 ± 7.4 years).
|
31261500 |
2019 |
Rheumatoid Arthritis
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
We discovered 280 TNF-inducible arthritogenic genes which are transiently expressed and subsequently repressed in macrophages, but in RA, FLS are expressed with prolonged kinetics that parallel the unremitting kinetics of RA synovitis.
|
31097419 |
2019 |
Rheumatoid Arthritis
|
0.700 |
Biomarker
|
disease |
BEFREE |
Of the disease-modifying antirheumatic drugs (DMARDs) used for RA treatment, methotrexate, triple combination oral therapy (methotrexate, sulfasalazine, and hydroxychloroquine), tumor necrosis factor inhibitor biologicals, and abatacept have the strongest data in favor of the reduction of cardiovascular events in patients with RA.
|
30953327 |
2019 |
Rheumatoid Arthritis
|
0.700 |
Biomarker
|
disease |
BEFREE |
Artesunate significantly inhibited the migration and invasion of RA-FLS in a dose-dependent manner with or without TNF-α stimulation.
|
31234900 |
2019 |
Rheumatoid Arthritis
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
This study was aimed to investigate the association of the single nucleotide polymorphism of tumor necrosis factor receptor associated factor 6 (TRAF6), rs540386, with low bone mineral density (BMD) among patients with rheumatoid arthritis (RA).
|
30506403 |
2019 |
Rheumatoid Arthritis
|
0.700 |
PosttranslationalModification
|
disease |
BEFREE |
Western blot assays were employed to examine c-Jun N-terminal kinase (JNK) expression and phosphorylation in TNF-α-induced HFLS-RA.
|
31258709 |
2019 |
Rheumatoid Arthritis
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Our results do not support a causal relationship between TNF expression, serum TNF-α levels, and RA on AD risk.
|
31587925 |
2019 |
Rheumatoid Arthritis
|
0.700 |
Biomarker
|
disease |
BEFREE |
Cost-Effectiveness of Sarilumab Added to Methotrexate in the Treatment of Adult Patients with Moderately to Severely Active Rheumatoid Arthritis Who Have Inadequate Response or Intolerance to Tumor Necrosis Factor Inhibitors.
|
31663465 |
2019 |
Rheumatoid Arthritis
|
0.700 |
Biomarker
|
disease |
BEFREE |
The clinical success of biologics that inhibit TNF (Tumor Necrosis Factor) in inflammatory bowel diseases (IBD), psoriasis and rheumatoid arthritis (RA) has clearly established a pathogenic role for this cytokine in these inflammatory disorders.
|
31457011 |
2019 |
Rheumatoid Arthritis
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Melatonin attenuates TNF-α and IL-1β expression in synovial fibroblasts and diminishes cartilage degradation: Implications for the treatment of rheumatoid arthritis.
|
30648758 |
2019 |